



Analyst: Neetika Gupta

Dallah Healthcare - 2Q23 Result Review

Previous Recommendation: Hold Target Price (SAR): 170.50 Previous TP & Date: 4% TP: SAR 170.50 per share on 22-May-2023 Current Upside / (Downside): 8/8/2023 Bloomberg Ticker DALLAH AB Current Market Price (SAR) 164.60 2,500 200.00 52wk High / Low (SAR) 189.8/113.8 12m Average Vol. (000) 145.5 2.000 150.00 Mkt. Cap. (USD/SAR mn) 4,114/15,434 1.500 Shares Outstanding (mn) 97.7 100.00 42% Free Float (%) 1,000 3m Avg Daily Turnover (000) 15.664.5 50.00 500 16,079.1 6m Avg Daily Turnover (000) P/E'23e (x) 48 9 0.00 0 EV/EBITDA'23e (x) 28.4 Jul-23 Aug-22 Dividend Yield '23e (%) 1.2% Volume, '000 (LHS) Price Perf. (1m/3m) (%) -0.5/-3 DALLAH AB. SAR (RHS)

Dallah's revenue growth in 2Q 2023 comes largely in line with our estimate

Dallah Healthcare registered a 15% YoY revenue growth in 2Q 2023 to SAR 670.4mn, largely in line with our estimate (+5% variance).

A faster increase in operating and non-operating costs YoY offsets healthy revenue growth. Consequently, operating and net profit misses our estimate

Dallah's direct costs jumped 17% YoY in 2Q 2023, because of which gross profit increased 11% YoY, slightly below the revenue growth, coming in line with our estimate. However, operating profit rose marginally by 2% YoY, missing our estimate by 14%, indicating a sharp rise in operating costs. Further, hit by higher finance costs and zakat provision, the company posted a 24% YoY dip in its net profit to SAR 53.0mn, below our estimate of SAR 75.5mn.

Maintain target price

Despite the unexpected performance at the operating profit and net profit levels, we would like to maintain our SAR 170.50 target price on the stock, awaiting the availability of detailed financials. Dallah's BoD has proposed SAR 0.5 per share dividend for 2Q 2023, matching our estimate and reflecting a 92% dividend payout.

Valuation

At the current market price, the stock is trading at around 49x P/E and 28x EV/EBITDA, based on our FY 2023 estimates, well above its 3-year daily average forward P/E of about 25x and EV/EBITDA of ~22x.

Income Statement												
(SAR mn)	2Q22	3Q22	4Q22	1Q23	2Q23	2Q23e	YoY (%)	QoQ (%)	Var (%)	1H 22	1H 23	YoY (%)
Sales/Revenue	583.8	600.9	693.9	716.6	670.4	640.3	15%	-6%	5%	1,193.2	1,387.1	16.2%
Gross Profit (Loss)	212.1	211.5	239.8	266.8	235.1	228.8	11%	-12%	3%	443.8	501.9	13.1%
Operating Profit (Loss)	100.9	84.2	101.7	138.1	102.9	120.2	2%	-25%	-14%	216.0	241.0	11.6%
Net Profit (Loss) after Zakat and tax	69.5	43.9	78.4	94.7	53.0	75.5	-24%	-44%	-30%	152.2	147.7	-2.9%
Balance Sheet												
(SAR mn)	2Q22	3Q22	4Q22	1Q23	2Q23	2Q23e	YoY (%)	QoQ (%)	Var (%)			
Shareholders' Equity	2,022.6	1,976.5	1,989.9	3,128.9	3,133.0	3,204.3	55%	0%	-2%			
Key Ratios												
	2Q22	3Q22	4Q22	1Q23	2Q23	2Q23e						
Gross Profit Margin	36.3%	35.2%	34.6%	37.2%	35.1%	35.7%						
Operating Profit Margin	17.3%	14.0%	14.7%	19.3%	15.4%	18.8%						
Net Profit Margin	11.9%	7.3%	11.3%	13.2%	7.9%	11.8%						
Return on Equity (RoE)	13.7%	8.9%	15.8%	12.1%	6.8%	9.4%						
Annualized EPS (SAR)	3.09	1.95	3.49	3.93	2.17	3.13						
BVPS (SAR)					32.07	32.80						
TTM P/E (x)					59.6							
Current P/BV (x)					5.1							
Source: Financials, Tadawul Disclosure, Bloomberg, U Capital Research												

For our earlier report on the sector, please click here.





Recommendation

BUY	Greater than 20%
ACCUMULATE	Between +10% and +20%
HOLD	Between +10% and -10%
REDUCE	Between -10% and -20%
SELL	Lower than -20%



Ubhar Capital SAOC (U Capital)

Website: www.u-capital.net
PO Box 1137
PC 111, Sultanate of Oman
Tel: +968 2494 9000
Fax: +968 2494 9099
Email: research@u-capital.net

Disclaimer: This report has been prepared by Ubhar Capital (U Capital) Research, and is provided for information purposes only. Under no circumstances is it to be used or considered as an offer to sell or solicitation of any offer to buy. While all reasonable care has been taken to ensure that the information contained therein is not untrue or misleading at the time of publication, we make no representation as to its accuracy or completeness and it should not be relied upon as such. The company accepts no responsibility whatsoever for any direct or indirect consequential loss arising from any use of this report or its contents. All

to change without notice. This report may not be reproduced, distributed or published by any recipient for any other purpose.

opinions and estimates included in this document constitute U Capital Research team's judgment as at the date of production of this report, and are subject